Evidence brief
Ipamorelin
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Still being studied; no FDA-approved product identified.
A short human study measured growth-hormone release, but it did not prove health benefits. A different phase 2 study did not show benefit on its main or other measured outcomes.
- How strong is the evidence?
- Emerging
Some studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation. - What evidence exists?
- Investigational human outcomes
Studies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain. - Sports rules
- Prohibited
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as ipamorelin acetate · NNC 26-0161 · growth hormone secretagogue
Part of Growth hormone peptides
Words used here
- phase 2
- a mid-stage study in people that checks effects and safety before larger studies
- outcome
- what the study measured
- investigational
- still being studied and not approved for that use
- molecule
- one specific chemical substance
- placebo
- an inactive treatment used for comparison
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- route
- how the product enters the body
- pharmacodynamics
- how a substance affects the body
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
A phase 2 trial did not show significant benefit on its key efficacy endpoint.
Dose-escalation work characterizes short-lived GH release in healthy volunteers.
Route-specific data are sparse and FDA identifies serious safety concerns.
No approved formulation anchors identity, purity, or equivalence in the consumer market.
02 · Identity
What it is
Ipamorelin can trigger the body to release growth hormone. Ipamorelin is a synthetic peptide that activates the ghrelin receptor and stimulates growth-hormone release. Human pharmacology studies and a clinical efficacy trial exist, making it a useful example of why biological activity and clinical benefit must be graded separately.
Scientific group: Ghrelin-receptor agonist · GH secretagogue. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- No FDA-approved indication
04 · Research results
What the research shows
The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.
Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.
Exact product
Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Ipamorelin stimulates GH release in people.”
A human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.
- Evidence used
- Human pharmacology. This answer uses a study of how the substance enters or changes the body in people. This alone does not show a health benefit.
- Limits of this answer
- Short-term GH pharmacodynamics in the healthy volunteers and route studied. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“A GH response proves better recovery or body composition.”
A biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Recovery and body-composition outcomes not established by GH pharmacology or the postoperative-ileus trial. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Ipamorelin worked in its phase 2 surgical trial.”
The randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- The postoperative-ileus population, intervention, and efficacy endpoints in the phase 2 trial. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Ipamorelin
Still being studied; no FDA-approved product identified. No approved product is identified in the United States.
Prohibited. Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework. This status is not personal clearance to compete.
The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.
Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.
07 · Safety
Safety limits for this record
FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.
Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed .Check current rules for tested sport ↗Open the governing record ↗08 · Sources
Read the sources
09 · Review history
Review history
Expanded trial-outcome, route, and product-quality boundaries.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.